Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Pharma Strategy Will Remove Barriers And Bolster Competition

Proposals Promise ‘Targeted Policies’ To Boost Generics And Biosimilars

Executive Summary

The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.

You may also be interested in...



EU’s Need For Digitalization Under Spotlight Again

Medicines for Europe has highlighted the need for an improved digital strategy across the EU in order to improve patient information and access to medicines, among other benefits like reducing the risk of supply disruptions, especially in the context of the current pandemic. 

EU Stakeholders Want More Focus On Availability Of Medicines

EU regulators have released their medicines network strategy to 2025 following a consultation that revealed broad support for its aim of ensuring the continued availability of medicines and accelerating innovation, but flagged up a number of areas where respondents wanted more clarity.

Biosimilars Must Play Key Role In EU Pharma Strategy

European policy makers must act quickly to harness the benefits of biosimilars as part of the new EU Pharma Strategy, Medicines for Europe insists in the wake of the latest annual report on European biosimilar competition.

Related Content

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel